Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Post ($0.34) EPS
Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has earned a consensus broker rating score of 1.13 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokers have set a 12 month consensus target price of $27.00 for the company and are predicting that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also given Clementia Pharmaceuticals an industry rank of 187 out of 265 based on the ratings given to related companies.
Several brokerages have weighed in on CMTA. Zacks Investment Research raised Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. Wedbush reissued an “outperform” rating and set a $26.00 price objective on shares of Clementia Pharmaceuticals in a report on Tuesday, November 14th.
Shares of Clementia Pharmaceuticals (NASDAQ:CMTA) traded up $0.43 during midday trading on Thursday, reaching $13.93. The company’s stock had a trading volume of 118,702 shares, compared to its average volume of 87,354. Clementia Pharmaceuticals has a 1-year low of $11.72 and a 1-year high of $20.15. The company has a market capitalization of $413.39 and a price-to-earnings ratio of -2.72.
TRADEMARK VIOLATION WARNING: This story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://theolympiareport.com/2018/02/22/analysts-expect-clementia-pharmaceuticals-inc-cmta-to-post-0-34-eps.html.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.